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Citrus Aurantium and caffeine complex
versus placebo on biomarkers of
metabolism: a double blind crossover
design
Brian Kliszczewicz* , Emily Bechke, Cassie Williamson, Zackery Green, Paul Bailey, John McLester and
Cherilyn McLester
Abstract
Backgrouond: The purpose of this study was to examine resting the metabolic response to the ingestion of a
complex containing Citrus Aurantium + Caffeine (CA + C) and if its consumption influences metabolic recovery
following a high-intensity anaerobic exercise bout in habitual caffeine users.
Methods: Ten physically active males (25.1 ± 3.9 years; weight 78.71 ± 9.53 kg; height 177.2 ± 4.6 cm; body fat 15.5 ±
3.13%) participated in this study. This study was performed in a double-blind, randomized crossover fashion
consisting of two exhaustive exercise protocols. On each visit the participants consumed either a CA + C (100 mg of
CA and 100 mg of C) or placebo (dextrose) capsule. After consumption, participants were monitored throughout a
45-min ingestion period, then completed a repeated Wingate protocol, and were then monitored throughout a 45-
min recovery period. Metabolic function was measured through blood glucose, plasma insulin, plasma triglycerides,
and plasma catecholamines: epinephrine (E) and norepinephrine (NE). Biomarkers were taken at four different time
points; Ingestion period: baseline (I1), post-ingestion period (I2); Recovery period: immediately post-exercise (R1),
post-recovery period (R2).
Results: A repeated measures ANOVA revealed significant time-dependent increases in plasma E and NE at I2 only
in the CA + C trial (p < 0.05), and a significant decrease in blood glucose at I2 in the PLA trial (p < 0.05); however, no
meaningful changes in glucose was observed following CA + C ingestion. No changes in insulin or triglycerides
were observed during the ingestion period. No trial-dependent differences were observed in the Recovery period.
All biomarkers of metabolic recovery were equivalent when evaluating R1 v R2. Participants recovered in a similar
time-dependent manner in all markers of metabolism following the PLA and CA + C trials.
Conclusion: The findings of this study suggested that normal recommended dosages of 100 mg CA + 100 mg C is
sufficient to promote glucose sparing at rest, with modest increases in SNS activity; however, the individual role of
CA or C in this response cannot be determined.
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Introduction
Thermogenic supplements have long been of interest to
those seeking to improve body composition and perform-
ance enhancement. Recently within the field of health and
fitness, the supplement complex of Citrus Aurantium and
Caffeine (CA + C) has been purported to assist in weight
loss through a number of physiological responses, such as
increased energy expenditure, increased oxidation of
lipids, and enhanced sympathetic drive [1, 2]. It is import-
ant to note that information regarding this complex is
relatively limited when evaluating metabolic responses
and should be further studied to determine the efficacy of
the claim that it can assist in improving metabolic
function.
Individually, the primary components of the CA +C
complex have demonstrated favorable responses in caloric
energy expenditure. For instance, the active component of
the Citrus Aurantium, p-synephrine, enhances sensitivity
to beta-3 receptors and improves lipolysis and resting me-
tabolism [1, 3, 4]. Whereas caffeine has been widely dem-
onstrated to increase various markers of exercise
performance in conjunction to energy expenditure [5, 6].
Few studies have fully examined the combined CA +C
complex in an isolated form; however, a recent study by
Ratamess et al. [2] showed improved lipolysis and energy
expenditure during rest with increases in fat oxidation fol-
lowing resistance-based exercise. These participants were
not identified as habitual users of caffeine, hence it is un-
known if the CA +C complex would be as effective in in-
dividuals that are habitual consumers.
Caffeine is perhaps one of the most widely utilized over
the counter supplements in the fitness industry [6, 7].
Therefore, it is likely that the target population of the CA
+C complex (i.e. athletes, fitness enthusiasts, etc.) would
be habitual caffeine consumers. With this in mind, it has
been demonstrated that habitual caffeine consumption
leads to decreases in the sensitivity to a regular dosage of
caffeine [8–11], (e.g. 100mg). Each individual component,
Citrus Aurantium and caffeine, primarily work through
beta-receptor function and consequently influence down-
stream metabolic activity such as the regulation of blood
glucose, insulin, triglycerides, and catecholamines. A de-
crease in caffeine responsiveness in habitual consumers
may result in a less robust metabolic response than those
reported in earlier studies [2]. Therefore, the purpose of
this study was to examine the resting metabolic profile be-
fore and after CA (100mg) + C (100mg) consumption.
Additionally, we aimed to evaluate post exercise metabolic
recovery following an exhaustive exercise protocol.
Methods
Participants
All testing procedures and protocols were approved by
the Universities’ Institutional Review Board prior to any
data collection. Fourteen apparently healthy males that
habitually consumed caffeine were recruited for this
study. Habitual caffeine consumption was defined as ≥
one 95mg serving per day, at least 4 days a week. Indi-
viduals who frequently consumed ≥300 mg/day of caf-
feine were excluded from the study. Physical activity
inclusion criteria required all individuals to take part in
no less than three-days of aerobic training and two-days
of resistance training every week for a minimum of six
months. Participants were recruited by word of mouth
from the nearby metropolitan region. Prior to participa-
tion, all subjects were provided with procedures and
made aware of risks associated with the study and the
informed consent was signed. A health history question-
naire (HHQ) was administered in order to ensure that
participants were able to take part in vigorous physical
activity without medical clearance as characterized by
the guidelines provided by American College of Sports
Medicine [12]. Individuals reporting of any orthopedic
conditions, cardiovascular, pulmonary, or metabolic dis-
ease were removed from the study. Participants were re-
quested to wear comfortable clothing, to arrive fasted
for a minimum of four-hours, avoid exercise and alcohol
for 24-h, and refrain from caffeine usage for 12-h pre-
ceding each session to ensure its clearance from the
blood [11].
Experimental design
This study was performed in a double-blind, placebo-
controlled, randomized crossover design where only one
investigator knew the identification of the supplementa-
tion; this investigator did not engage in the gathering or
analysis of data. Participants were requested to attend
the Exercise Physiology Lab on two separate occasions,
with the second visit taking place within three to nine
days after the first visit. All visits were performed be-
tween 5 and 7 am. The initial visit comprised of obtain-
ing the informed consent, HHQ, and anthropometric
measures. Participant height (cm) and weight (kg) were
gathered using an electronic physicians scale (Tanita WB
3000, Arlington Heights, IL). Body fat (BF%) was gath-
ered via dual-energy x-ray absorptiometry scan (GE
Lunar iDXA, Madison, WI) during the first visit using
manufacturer’s guidelines and recommendations.
The remaining two visits can be described in two over-
arching sections; the ingestion period with pre and post
time points (I1 & I2) and the recovery period with pre
and post time points (R1 & R2). The ingestion period
consisted of baseline measures (I1), which included
venipuncture, followed by the consumption of either the
supplement (CA + C) or placebo (PLA). The 45-min in-
gestion period was initiated after the participants con-
sumed CA + C or PLA. Upon the completion of the
ingestion period, a post-ingestion venipuncture was
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performed (I2). Participants then performed a standard-
ized warm-up prior to initiating the anaerobic exhaustive
exercise protocol. Immediately following the exercise
protocol a post-exercise venipuncture was performed
(R1) and then the 45-min recovery period was initiated.
At the end of this recovery period the final venipuncture
was taken (R2). The study design can be seen in Fig. 1.
Exhaustive exercise protocol
Upon the completion of the 45-min ingestion period, par-
ticipants were allotted a seven-and-a-half minute warm
up on a Monark ergometer (Monark 828E Ergomedic Test
Cycle, Vansbro, Sweden) while pedaling between 50 and
100 rpm at a resistance of 1.5 kp. Participants were imme-
diately walked to an electronically braked cycle ergometer
(Sport Excalibur, Lode BV, Groningen, The Netherlands),
where the bike was adjusted to the appropriate settings in
order to ensure the knee was at a slight bend at the bot-
tom of the revolution. Bike settings were repeated for both
trials. Following the appropriate adjustments, participants
feet were strapped into the pedals and the protocol was
initiated. The start of the exhaustive exercise protocol
comprised of a one-minute warm-up period performed at
50W with a rolling start into the Wingate test. Each Win-
gate test was 30-s in duration and participants were en-
couraged to pedal at their maximal effort against a
resistance of 0.80 Nm/kg [13]. There was a total of three
Wingate tests performed with a two-minute active recov-
ery period between each test. The active recovery was a
self-selected pedal rate against a resistance of 50W and a
rolling start into the subsequent Wingate test. At the
completion of the last Wingate test, participants were
walked to a separate room to undergo a post exercise
venipuncture and to begin the recovery measures (R1-R2).
Pre-testing protocols on the electronically braked cycle
ergometer followed manufacturer guidelines.
Blood collection and analysis
Blood draws were collected via the antecubital vein by a
trained phlebotomist during four-time points throughout
the study: I1, I2, R1, R2 (Fig. 1). Each draw obtained six
milliliters of blood using lithium heparin tubes and were
inverted based on the manufactures’ recommendations
prior to centrifugation. Samples were centrifuged at 2500
rpm for 15-min, then aliquoted and stored in a − 80 °C
freezer until subsequent assay analysis. Plasma samples
were assayed using commercially available ELISA kits for
Insulin (Alpco, Salem, New Hampshire), Triglycerides (In-
finity™, Thermo Scientific, Lexington, Massachusetts), E
and NE (Abnova, Taoyuan City, Taiwan). In order to ac-
count for the plasma volume shifts following the exercise
bout, all E and NE samples were normalized by using the
established protocols of Dill and Costill [14]. Hematocrit
(Hct) and hemoglobin (Hb) were collected via finger sticks
at each venipuncture time point (Alere Hemopoint 2).
Blood glucose (GLU) was measured using a Medtronic
Contour glucometer (Bayer, Pittsburgh, PA) via finger
stick. The procedures and findings of plasma catechol-
amines were previously reported and permissions granted
by the publishing Journal [15].
Supplement preparation
Citrus Aurantium and caffeine powder were purchased
from Blackburn distributions (Caffeine powder, Black-
burn distributions limited, Nelson Lancashire, England;
Citrus Aurantium powder, Blackburn distributions lim-
ited, Nelson Lancashire, England). The PLA contained
200 mg of dextrose, whereas the supplement contained a
combination of CA (100 mg) and C (100 mg). Each com-
ponent was measured using an electronic supplement
scale and encapsulated in green, non-translucent, size
zero gelatin capsules.
Statistical analysis
All data were analyzed using the statistical software
package SPSS (SPSS, Version 24 for Mac, Chicago, IL).
In order to assess changes in time within trial (CA + C/
PLA) repeated measures analysis of variance (ANOVA)
were run (I1 vs I2 and R1 vs R2) in the metabolic bio-
markers glucose, insulin, and triglycerides. Significance
for all statistical analyses was set at ≤0.05. The data is
presented as the mean ± standard deviation (SD). In
order to determine the effect size, the recommend
guidelines of Quintana were used. [16]. Thresholds for
Fig. 1 Study Design
Kliszczewicz et al. Journal of the International Society of Sports Nutrition            (2019) 16:4 Page 3 of 7
effect size were the following; a small (< 0.25) moderate
(0.50), and large effect (0.90).
Results
Of the fourteen participants who volunteered for the
study, four were removed due to adverse reactions to
the phlebotomy procedure (i.e. vaso-vagal reactions) (n
= 2), pain brought on by brochiospasm (n = 1), and trial
monitoring issues (n = 1). Therefore, a total of ten phys-
ically active males completed the study. Participant char-
acteristics can be seen in Table 1.
Insulin
Repeated measures ANOVA showed no main effect be-
tween the trials in insulin (p = 0.198) while no significant
time differences were observed when comparing I1 to I2
during the ingestion periods for PLA (p = 0.151) or for
CA + C (p = 0.061) or -R1 to R2 during the recovery pe-
riods (p = > 0.999, p = 0.339), respectively (Fig. 2).
Glucose
The repeated measures ANOVA showed a main trial ef-
fect (p = 0.045) in blood glucose. Specifically, I2 PLA
was significantly lower when compared to I2 CA + C (p
< 0.001, Cohen’s d 1.701). When evaluating PLA I1 vs I2
a significant decrease was observed (p = 0.04, Cohen’s d
0.839), while a no change in concentration was seen in
the CA + C trial (p = 0.714). Both trials observed signifi-
cant reductions in blood glucose when comparing R1 to
R2 (p = 0.01, Cohen’s d 2.078; p < 0.001, Cohen’s d
2.586), respectively (Fig. 3).
Triglycerides
The repeated measures ANOVA showed no main trial
effect in plasma triglycerides (p = 0.529). Additionally, no
significant time-based differences were observed when
comparing the I1 vs I2 for PLA (p = 0.25) or for CA + C
(p = 0.993). Both trials demonstrated a time-dependent
decrease when evaluating R1 vs R2 (p = 0.001, Cohen’s d
0.582; p = 0.004, Cohen’s d 0.868), respectively. Means ±
SD can be seen in Fig. 4.
Catecholamines
The repeated measures ANOVA showed no significant
trial-based differences between E or NE during the CA
+ C and PLA ingestion or recovery periods. A significant
time-effect was observed during form I1 to 12 only in
the CA + C trial for plasma E (p = 0.02, Cohen’s d 0.58)
and NE (p < 0.001, Cohen’s d 1.73). Both CA + C and
PLA trials demonstrated time-based decreases between
R1 and R2 in E (p < 0.001, Cohen’s d 1.74; p < 0.001,
Cohen’s d 2.00) and NE (p < 0.001, Cohen’s d 3.20; p <
0.001, Cohen’s d 2.17) respectively. Means ± SD can be
seen in Figs. 5 & 6, [15].
Discussion
The primary purpose of this study was to examine the
claim that CA + C supplementation can alter resting
metabolic profile, with a secondary aim to evaluate
post-exercise metabolic recovery following an exhaustive
exercise protocol in habitual caffeine consumers. The
major findings of the study indicate that CA +C con-
sumption resulted in a maintenance of glucose levels fol-
lowing the ingestion period, while a significant drop
occurred following the consumption of the PLA. No sig-
nificant trial differences occurred in insulin, lactate or tri-
glycerides throughout the ingestion period. The recovery
period for both the CA +C and the PLA trials reveled no
trial-based differences.
Table 1 Participant Characteristics (N = 10)
Characteristic Mean ± SD
Age (y) 25.1 ± 3.8
Height (cm) 177.2 ± 4.6
Weight (kg) 78.8 ± 9.4
Body Fat (%) 15.5 ± 3.0
Caffeine/day (mg) 209 ± 95.5
Fig. 2 Plasma Insulin. Plasma insulin is presented as Means ± SD
and expressed in International Units (mU·L− 1). * = significantly
different from I1. + = Significantly different from PLA. # = Significantly
different from R1
Fig. 3 Blood Glucose. Blood glucose is presented as Means ± SD
and expressed in mg/dL. * = significantly different from I1. + =
Significantly different from PLA. # = Significantly different from R1
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Ingestion
The ingestion period of the study occurred over a
45-min time frame in a quiet, relaxed setting following
the consumption of CA + C or PLA. Under normal
fasted conditions it is not uncommon to observe a slight
decrease in blood glucose with concurrent decreases in
insulin concentration over a prolong period of rest [17,
18]. Blood glucose concentration following the PLA trial
is reflective of this response, with a significant drop oc-
curring at I2. Interestingly, the CA + C ingestion period
did not follow this trend. No changes in glucose concen-
tration occurred and was found to be significantly higher
than that of the PLA trial at the I2 time point. The glu-
cose response following the CA + C trial is closer to
those found by Ratamess et al. [2], who observed a sig-
nificant increase in concentration following the 45-min
ingestion period of p-synephrine + caffeine. However,
the Ratamess study observed equivalent changes in
blood glucose following the 45-min ingestion periods in
the placebo, p-synephrine, and p-synephrine + caffeine
trials. This increase in blood glucose could be attributed
to the 16 g of carbohydrate used in their supplement
compound [2]. The medium by which the supplements
were delivered in the current study were capsules absent
of carbohydrate and would rationalize the difference in
observations between the two studies.
Similar to glucose, insulin has been shown to be main-
tained or decrease during resting and fasted conditions
[19]. The findings in our study are supportive of the ex-
pected response, with insulin concentration being main-
tained in both PLA and CA + C throughout the
ingestion period. This is in contrast to Graham et al.
[20] who found that caffeine supplementation signifi-
cantly elevated serum insulin levels when compared to
placebo during an oral glucose tolerance test. However,
the differences in observations can likely be attributed to
the dosage of caffeine Graham et al. [20] used, which
was almost five times greater than that of the current
study. Though there were no apparent changes in the
concentration of insulin following the CA + C trial, sev-
eral studies have demonstrated that caffeine causes a de-
crease in insulin sensitivity [21]. This may be a possible
mechanism explaining the glucose maintenance ob-
served following the CA + C consumption.
The caffeine components role in sympathetic nervous
system (SNS) mediated glucose release [22] may be an-
other likely contributor to the observed glucose re-
sponse. Following the consumption of CA + C, both
plasma E and NE significantly increased, while no
changes occurred with the PLA trial. This is in agree-
ment with Graham and Spriet [23], who observed a
two-time increase in plasma E following the consump-
tion of 9 mg/kg of caffeine. Additionally, Stuart et al.
[24], demonstrated a significantly higher level of plasma
E 70-min following the consumption of 6 mg/kg of caf-
feine when compared to the placebo group. The caffeine
concentration given in this trial was a single dose of 100
mg (1.13–1.44 mg/kg), which is far less than the exam-
ined dosages of the aforementioned studies. This may in
part explain the modest increase in E and NE observed
at I2 in the CA + C trial and consequent glucose main-
tenance as opposed to more robust glucose responses
observed in other studies [22]. The CA component of
Fig. 4 Plasma Triglycerides. Plasma triglycerides are presented as
Means ± SD and expressed in mg/dL. * = significantly different from
I1. + = Significantly different from PLA. # = Significantly different
from R1
Fig. 5 Plasma Epinephrine. Plasma epinephrine is presented as
Means ± SD and expressed in nmol/L. * = significantly different from
I1. + = Significantly different from PLA. # = Significantly different
from R1
Fig. 6 Plasma Norepinephrine. Plasma norepinephrine is presented
as Means ± SD and expressed in nmol/L. * = significantly different
from I1. + = Significantly different from PLA. # = Significantly different
from R1
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the complex is another mechanism by which the main-
tenance of blood glucose could have occurred. Specific-
ally, the active ingredient p-synephrine acts on beta-3
receptors in order to increase lipolysis [1], thereby acting
to spare blood glucose. However, the findings in our
study do not suggest this due to triglycerides remaining
unchanged following the consumption of PLA or CA +
C. Overall, the present study suggests that the consump-
tion of CA + C in the current dosage appears to promote
glucose maintenance at resting conditions. Future re-
search should examine varying concentrations in order
to determine a dose effect.
Recovery
The exhaustive exercise trial selected for this study was
a repeated Wingate protocol designed to induce a high
metabolic stress and fatigue. Following the completion
of the trials, no differences in glucose, insulin, triglycer-
ides, or catecholamines were observed. Blood glucose
nearly doubled for both CA + C and PLA compared to
baseline values, which indicates a normal metabolic
response to an acute high intensity protocol [25]. How-
ever, insulin did not statistically elevate immediately
post-exercise but demonstrated a non-statistical increase
at the end of the recovery period. Previous research has
demonstrated insulin spikes immediately following
prolonged high-intensity protocols [25]; however, the
duration of those protocols was ultimately longer than
the one used previous studies and may have led to the
different insulin response. Though fat oxidation was not
directly measured throughout this study, plasma triglycer-
ides were obtained to determine changes in metabolic
function. A primary function of the Citrus Aurantium is
improved lipid peroxidation through p-synephrine and
beta-3 activation, which may alter the release of triglycer-
ides following exercise based on demand, and ultimately
influence metabolic recovery. Post-exercise plasma triglyc-
erides have been shown to account for half of the delayed
component of excess post exercise oxygen consumption
(EPOC) [26, 27], which is a beneficial response to
high-intensity exercise. Interestingly, both trials showed
spikes in plasma triglycerides at R1 when compared to I2,
though no difference was observed between trials. Follow-
ing the 45-min recovery, both trials demonstrate similar
rates in recovery in triglycerides, suggesting that CA + C
had no influence.
Though this study was a novel attempt to evaluate the
general metabolic responses to the consumption of the
CA + C complex, it was not without its limitations. Cur-
rently there is no recommended dosage for the CA + C
complex, and the current concentrations selected for
this study was based on previous research [2]. The pri-
mary purpose of the study was to evaluate the CA + C
complex; however, future research should examine the
individual components to determine a causal relation-
ship. Furthermore, various dosages of this complex
should be evaluated in order to better determine a
dose-response effect. The markers used to examine me-
tabolism were glucose, insulin, and triglycerides; future
research should examine a more extensive metabolic
profile including substrate utilization and free fatty acids.
Though a priori analysis based on a power of 0.8, alpha
level of 0.05, and effect size of 0.3 determined the neces-
sary n size to be 10 [28], a larger population sample
should be used in order to better evaluate effects and
trends.
Conclusion
The commercial use of the CA + C supplement is based
around the belief that metabolic function is enhanced
following its consumption [2]. The findings of this study
suggested that normal recommended dosages of 100 mg
CA + 100mg C were sufficient to promote glucose spar-
ing at rest, with modest increases in SNS activity. How-
ever, this was not enough to elicit changes in resting
insulin, or triglycerides. These findings suggest practical
implications of hypoglycemic prevention during prolong
(i.e. 45-min) fasted periods. The CA + C complex exam-
ined in this study provided a minimal metabolic re-
sponse following its ingestion; however, the individual
role of CA or C in this response cannot be determined.
Further research is needed to examine a dose and com-
ponent response on these metabolic markers.
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